


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Formula (I) compounds




in which

the various R1, R2, R3 and R4, which can be the same or different, are H, OH, OPO3H2 or OCH2OPO3H2 and their disodium salt, OMe, OCH2O, NO2, F, Cl, Br;

-R1-R2- can also be together: -CR8=CR9-X-


Y is a group selected from



R5 and R6, which can be the same or different, are H or halogen;

R7 is H, OMe, SO2Ph;

Ar is a group selected from:



R8, R9 and R10, which can be the same or different, are H, OH, OPO₃H₂ or OCH₂OPO₃H₂ and their disodium salt, OR₁₁, OCH₂O, NH₂, NHR₁₁, NO₂, alkyl (C₁-C₄), C₆H₅, C₅H₄N or halogen;

R₁₁ is C₁-C₄ alkyl or acyl, aminoacids residue;

X is O, S, N, NR₁₂;

R₁₂ is H, CH₃, CH₂Ph;

Z is CH, N;

with the proviso that the formula (I) compound is not combretastatin A-1, combretastatin A-2, combretastatin A-4, and their disodium phosphates derivatives and with the exclusion of the following compounds:

2-phenyl-6-*trans*-styryl-benzo[b]furan;

2,3-diphenyl-6-*trans*-styryl-benzo[b]furan;

2-phenyl-6-(4-methoxy)-*trans*-styryl-benzo[b]furan;

2-phenyl-6-(3,4-dimethoxy)-*trans*-styryl-benzo[b]furan;

2-phenyl-6-(3,4,5-trimethoxy)-*trans*-styryl-benzo[b]furan;

2-phenyl-6-(3,4-methylenedioxy)-*trans*-styryl-benzo[b]furan;

2,3-diphenyl-6-(4-methoxy)-*trans*-styryl-benzo[b]furan;

2-phenyl-5-*trans*-styryl-benzo[b]thiophene;

2-phenyl-5-(4-methoxy)-*trans*-styryl-benzo[b]thiophene;

2-phenyl-5-(3,4-methylenedioxy)-*trans*-styryl-benzo[b]thiophene;

2-phenyl-6-*trans*-styryl-benzo[b]thiophene;

2-phenyl-6-(4-methoxy)-*trans*-styryl-benzo[b]thiophene;

2-phenyl-6-(4-chloro)-*trans*-styryl-benzo[b]thiophene;

Piceatannol;

1-(3-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;

1-(3-thiophenyl)-2-(3,4,5-trimethoxyphenyl)ethene;

1-(2-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;

and with the proviso that

- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not methoxy;

- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 2-chloro, R10 is not 4-methoxy;

- when R1 is hydrogen and R2-R4 are trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8-R10 is not hydrogen;

- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is none of 4-chloro, 4-bromo, 4-nitro, 4-hydroxy, 4-acetyl, 4-ethoxy, 4-C1-C4 alkyl;

- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-nitro or 4-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;

- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-nitro or 3-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

- when R1 is hydrogen and R2- R4 are 2,3,4-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 is hydrogen, R9 is 3-methoxy, R10 is not 5-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 -R10 are not methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9-R10 are not 3,5-dimethoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8-R10 is not hydrogen;
- when R1 and R2 are hydrogen and R3-R4 are 3,5-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,5-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-acetyl;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is not pyridyl;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is 4-NHR11, R11 is not the residue of serine;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373


- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not a 4-alkyloxy group having from 1 to 3 carbon atoms, or a 4-alkyl group having from 1 to 4 carbon atoms, or a halogen atom
- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 5-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 2,3,4-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of serine, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of the aminoacid cysteine, glycine, phenylalanine, serine, triptophan, tyrosine, valine, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NO₂ or NH₂, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 -R10 is not hydrogen;

- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methyl, R10 is not 3-fluoro or 3-hydroxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is 3-fluoro, R9 is 4-methoxy, R10 is not 2- or 5-fluoro;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3- hydroxy or 3-amino;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro or 3-bromo;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-hydroxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-methyl, R10 is not 4-methyl;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-hydroxy;
- when R1- R2 are hydrogen and R3-R4 are 3,5-dihydroxy, Y is *trans* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-hydroxy, R10 is not 5-hydroxy;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

- when R1-R3 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, and R4 is not 4-methoxy;
- when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, R4 is 4-methoxy, R3 is not 3-fluoro or 3-bromo or 3-nitro or 3-hydroxy;
- when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R10 are 3,4,5-triethoxy, R4 is 4-methoxy, R3 is not 3-fluoro or 3-chloro or 3-bromo or 3-hydroxy;
- when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-hydroxy, R3 is not 3-fluoro or 3-hydroxy;
- when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-methoxy, R3 is not 3-fluoro;
- when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8- R10 is not hydrogen;
- when R1 and R2 are hydrogen, R3 is 3-hydroxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8- R10 is not hydrogen;
- when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy,
Y is



Ar is indolyl, wherein at least one of R⁸-R¹⁰ is different from hydrogen;

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

2. (Original) Compound according to claim 1, selected from the group consisting of:

2-methoxy-5-[3-methoxy-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-4-isoxazolyl]-phenol;

2-methoxy-5-[3-methoxy-4-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-phenol;

5-[3-benzenesulphonyl-4-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-4-isoxazolyl]-2-methoxy-phenol;

5-[3-benzenesulphonyl-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxy-phenol;

2-methoxy-5-[3-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-phenol;

2-methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-3-isoxazolyl]-phenol;

2-methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-3-isoxazole]-phenol;

cis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;

trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thio-phen-4-ol;

cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophene;

trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thio-phen-4-ol;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

cis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;
trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;
cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;
trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;
cis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-7-ol;
trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-7-ol;
cis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol ;
trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol ;
cis-1-methoxy-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalene;
methoxy-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalene;
cis-7-methoxy-1-methyl-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-1H-indazole;
trans-7-methoxy-1-methyl-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-1H-indazole;
2-nitro-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-thiophene;
2-nitro-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-furan;
cis-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;
trans-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;
disodium 6[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-phosphate;
disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-phosphate;
6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;
6-[(E)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;
6[(Z)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;
6[(E)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

disodium 6[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-methyloxyphosphate;

disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-methyloxyphosphate;

6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;

6-[(E)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol .

6[(Z)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;

6[(E)-2-(3-methoxy-4,5-methylenedioxy-phenil-1-yl)-vinyl]-1-benzofu-ran-4-ol;

disodium 6[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-methyloxyphosphate;

disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-methyloxyphosphate;

6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;

cis-2-Methoxy-5-[2-(4-methoxy-benzofuran-6-yl)-vinyl]-phenol;

cis-2-Methoxy-5-[2-(7-methoxy-benzofuran-5-yl)-vinyl]-phenol;

cis-2-Methoxy-5-[2-(4-methoxy-benzo[b]thiophen-6-yl)-vinyl]-phenol;


cis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;

cis-5-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-7-ol;

cis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-4-ol;

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

3. (Original) Use of formula (I) compounds




in which

the various R1, R2, R3 and R4, which can be the same or different, are H, OH, OPO₃H₂ or OCH₂OPO₃H₂ and their disodium salt, OMe, OCH₂O, NO₂, F, Cl, Br;

-R1-R2- can also be together: -CR₈=CR₉-X-


Y is a group selected from



R5 and R6, which can be the same or different, are H or halogen;

R7 is H, OMe, SO₂Ph;

Ar is a group selected from:



SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

R8, R9 and R10, which can be the same or different, are H, OH, OPO₃H₂ or OCH₂OPO₃H₂ and their disodium salt, OR₁₁, OCH₂O, NH₂, NHR₁₁, NO₂, alkyl (C₁-C₄), C₆H₅, C₅H₄N or halogen;

R₁₁ is C₁-C₄ alkyl or acyl, aminoacids residue;

X is O, S, N, NR₁₂;

R₁₂ is H, CH₃, CH₂Ph;

Z is CH, N;

with the proviso that the formula (I) compound is not combretastatin A-1, combretastatin A-2, combretastatin A-4, and their disodium phosphates derivatives and with the exclusion of the following compounds:

Piceatannol;

1-(3-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;

1-(3-thiophenyl)-2-(3,4,5-trimethoxyphenyl)ethene;

1-(2-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;

and with the proviso that

- when R₁ is hydrogen and R₂- R₄ are 3,4,5-trimethoxy, Y is a double bond, R₅ and R₆ are H, Ar is phenyl, R₈ and R₉ are hydrogen, R₁₀ is not methoxy;

- when R₁ is hydrogen and R₂- R₄ are 3,4,5-trimethoxy, Y is a double bond, R₅ and R₆ are H, Ar is phenyl, R₈ is hydrogen, R₉ is 2-chloro, R₁₀ is not 4-methoxy;

- when R₁ is hydrogen and R₂-R₄ are trimethoxy, Y is a double bond, R₅ and R₆ are H, Ar is phenyl, at least one of R₈-R₁₀ is not hydrogen;

- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is none of 4-chloro, 4-bromo, 4-nitro, 4-hydroxy, 4-acetyl, 4-ethoxy, 4-C1-C4 alkyl;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-nitro or 4-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-nitro or 3-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;
- when R1 is hydrogen and R2- R4 are 2,3,4-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 is hydrogen, R9 is 3-methoxy, R10 is not 5-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 -R10 are not methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9-R10 are not 3,5-dimethoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8-R10 is not hydrogen;

- when R1 and R2 are hydrogen and R3-R4 are 3,5-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- when R1 and R2 are hydrogen and R3-R4 are 3,5-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-acetyl;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is not pyridyl;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is 4-NHR11, R11 is not the residue of serine;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2- R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not a 4-alkyloxy group having from 1 to 3 carbon atoms, or a 4-alkyl group having from 1 to 4 carbon atoms, or a halogen atom
- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 5-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 2,3,4-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of serine, R10 is not 4-methoxy;

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of the aminoacid cysteine, glycine, phenylalanine, serine, triptophan, tyrosine, valine, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NO2 or NH2, R10 is not 4-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 -R10 is not hydrogen;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methyl, R10 is not 3-fluoro or 3-hydroxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-methoxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is 3-fluoro, R9 is 4-methoxy, R10 is not 2- or 5-fluoro;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3- hydroxy or 3-amino;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro or 3-bromo;

- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-hydroxy;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-methyl, R10 is not 4-methyl;
- when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-hydroxy;
- when R1- R2 are hydrogen and R3-R4 are 3,5-dihydroxy, Y is *trans* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-hydroxy, R10 is not 5-hydroxy;
- when R1-R3 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, and R4 is not 4-methoxy;
- when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, R4 is 4-methoxy, R3 is not 3- fluoro or 3-bromo or 3-nitro or 3-hydroxy;
- when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R10 are 3,4,5-triethoxy, R4 is 4-methoxy, R3 is not 3-fluoro or 3-chloro or 3-bromo or 3-hydroxy;
- when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-hydroxy, R3 is not 3-fluoro or 3-hydroxy;
- when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-methoxy, R3 is not 3-fluoro;
- when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8- R10 is not hydrogen;


SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

- when R1 and R2 are hydrogen, R3 is 3-hydroxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8- R10 is not hydrogen;

- when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy,

Y is



Ar is indolyl, wherein at least one of R8-R10 is different from hydrogen;

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts as medicaments.

4. (Original) Use according to claim 3 for the preparation of a medicament for the treatment of oncological-type diseases.

5. (Original) Use according to claim 3 for the preparation of a medicament for the treatment of cancers that respond to cytotoxic activity.

6. (Original) Use according to claim 5, in which said cancer is selected from the group consisting of sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, lymphoid leukaemia, myeloid leukaemia, monocytic leukaemia, megakaryocytic leukaemia, or Hodgkin's disease.

7. (Original) Use of compounds according to claim 1 for the preparation of a medicament for the treatment of diseases related to abnormal angiogenesis.


8. (Original) Use according to claim 7, in which said disease is selected from the group consisting of arthritic disease, tumours responding to antiangiogenic activity, metastatic spread, diabetic retinopathy, psoriasis, chronic inflammation, and atherosclerosis.

9. (Currently Amended) Use according to ~~any one of claims~~ claim 4 to 8, in which, in the treatment of tumours, said medicament is combined with at least one other antitumour drug.

10. (Original) Use according to claim 9, in which said antitumour drug is selected from the group consisting of alkylating agents; topoisomerase inhibitors; antitubulin agents; intercalating agents; antimetabolites; naturally occurring products such as Vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxanes and anticancer vaccines.

11. (Currently Amended) Pharmaceutical composition containing as the active ingredient a compound according to ~~claims~~ claim 1-2 or disclosed in ~~claim 3~~ in a mixture with a pharmaceutically acceptable excipient or diluent.


12. (Currently Amended) Use of the compound with the formula



in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to ~~claims~~ claim 1-2.


13. (Original) Compound with the formula:



in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

14. (Original) Compound with the formula



in which


X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

R1 is formyl.

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373


15. (Currently Amended) Use of the compound with the formula



in which


X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to ~~claims~~ claim 1-2.

16. (Original) Compound with the formula



in which

X is oxygen or sulphur.



17. (Original) Compound with the formula

SIMONI et al.

New National Phase Application Based on PCT/IT2004/000373

in which

X is oxygen or sulphur.

Claim 18 (Cancelled)